Frontiers in Medicine (Apr 2021)
The Possible Non-Mutational Causes of FVIII Deficiency: Non-Coding RNAs and Acquired Hemophilia A
- Alina-Andreea Zimta,
- Ionut Hotea,
- Ionut Hotea,
- Melen Brinza,
- Melen Brinza,
- Cristina Blag,
- Cristina Blag,
- Sabina Iluta,
- Catalin Constantinescu,
- Catalin Constantinescu,
- Atamyrat Bashimov,
- Elisabeth-Antonia Marchis-Hund,
- Alexandra Coudsy,
- Laetitia Muller-Mohnssen,
- Noemi Dirzu,
- Diana Gulei,
- Delia Dima,
- Margit Serban,
- Margit Serban,
- Margit Serban,
- Daniel Coriu,
- Daniel Coriu,
- Ciprian Tomuleasa,
- Ciprian Tomuleasa,
- Ciprian Tomuleasa
Affiliations
- Alina-Andreea Zimta
- Medfuture Research Center for Advanced Medicine, Iuliu Hatieganu University of Medicine and Pharmacy, Cluj Napoca, Romania
- Ionut Hotea
- Department of Hematology, Iuliu Hatieganu University of Medicine and Pharmacy, Cluj Napoca, Romania
- Ionut Hotea
- Department of Hematology, Ion Chiricuta Clinical Cancer Center, Cluj Napoca, Romania
- Melen Brinza
- Department of Hematology, Fundeni Clinical Institute, Bucharest, Romania
- Melen Brinza
- Department of Hematology, Carol Davila University of Medicine and Pharmacy, Bucharest, Romania
- Cristina Blag
- Department of Pediatrics, Iuliu Hatieganu University of Medicine and Pharmacy, Cluj Napoca, Romania
- Cristina Blag
- Department of Hematology, Emergency Clinical Children's Hospital, Cluj Napoca, Romania
- Sabina Iluta
- Department of Hematology, Iuliu Hatieganu University of Medicine and Pharmacy, Cluj Napoca, Romania
- Catalin Constantinescu
- Department of Hematology, Iuliu Hatieganu University of Medicine and Pharmacy, Cluj Napoca, Romania
- Catalin Constantinescu
- Intensive Care Unit, Clinical Hospital for Infectious Diseases, Cluj Napoca, Romania
- Atamyrat Bashimov
- Medfuture Research Center for Advanced Medicine, Iuliu Hatieganu University of Medicine and Pharmacy, Cluj Napoca, Romania
- Elisabeth-Antonia Marchis-Hund
- Medfuture Research Center for Advanced Medicine, Iuliu Hatieganu University of Medicine and Pharmacy, Cluj Napoca, Romania
- Alexandra Coudsy
- Medfuture Research Center for Advanced Medicine, Iuliu Hatieganu University of Medicine and Pharmacy, Cluj Napoca, Romania
- Laetitia Muller-Mohnssen
- Medfuture Research Center for Advanced Medicine, Iuliu Hatieganu University of Medicine and Pharmacy, Cluj Napoca, Romania
- Noemi Dirzu
- Medfuture Research Center for Advanced Medicine, Iuliu Hatieganu University of Medicine and Pharmacy, Cluj Napoca, Romania
- Diana Gulei
- Medfuture Research Center for Advanced Medicine, Iuliu Hatieganu University of Medicine and Pharmacy, Cluj Napoca, Romania
- Delia Dima
- Department of Hematology, Iuliu Hatieganu University of Medicine and Pharmacy, Cluj Napoca, Romania
- Margit Serban
- Louis Turcanu Emergency Children's Hospital, Timisoara, Romania
- Margit Serban
- 0European Hemophilia Treatment Center, Timisoara, Romania
- Margit Serban
- 1Department of Pediatrics, Victor Babes University of Medicine and Pharmacy, Timisoara, Romania
- Daniel Coriu
- Department of Hematology, Fundeni Clinical Institute, Bucharest, Romania
- Daniel Coriu
- Department of Hematology, Carol Davila University of Medicine and Pharmacy, Bucharest, Romania
- Ciprian Tomuleasa
- Medfuture Research Center for Advanced Medicine, Iuliu Hatieganu University of Medicine and Pharmacy, Cluj Napoca, Romania
- Ciprian Tomuleasa
- Department of Hematology, Iuliu Hatieganu University of Medicine and Pharmacy, Cluj Napoca, Romania
- Ciprian Tomuleasa
- Department of Hematology, Ion Chiricuta Clinical Cancer Center, Cluj Napoca, Romania
- DOI
- https://doi.org/10.3389/fmed.2021.654197
- Journal volume & issue
-
Vol. 8
Abstract
Hemophilia type A (HA) is the most common type of blood coagulation disorder. While the vast majority of cases are inherited and caused by mutations in the F8 gene, recent data raises new questions regarding the non-heritability of this disease, as well as how other molecular mechanisms might lead to the development of HA or increase the severity of the disease. Some data suggest that miRNAs may affect the severity of HA, but for some patients, miRNA-based interference might cause HA, in the absence of an F8 mutation. A mechanism in HA installation that is also worth investigating and which could be identified in the future is the epigenetic silencing of the F8 gene that might be only temporarily. Acquired HA is increasingly reported and as more cases are identified, the description of the disease might become challenging, as cases without FVIII autoantibodies might be identified.
Keywords
